白介素13(IL13)活性蛋白

[ PROPERTIES ]

Source: Prokaryotic expression. Host: E. coli

Residues: Pro22~His131

Tags: N-terminal His-tag

Purity: >85%

Buffer Formulation: 100mM NaHCO3, 500mM NaCl, pH8.3, containing 1mM

DTT, 0.01% sarcosyl, 5%Trehalose and Proclin300. Applications: Cell culture; Activity Assays. (May be suitable for use in other assays to be determined by the end user.)

Predicted isoelectric point: 8.6

Predicted Molecular Mass: 15.8kDa

Accurate Molecular Mass: 16kDa as determined by SDS-PAGE reducing conditions.

[ USAGE ]

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0mg/mL. Do not vortex. 

[ STORAGE AND STABILITY ]

Storage: Avoid repeated freeze/thaw cycles. 

Store at 2-8^oC for one month. Aliquot and store at -80^oC for 12 months.

Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37^oC for 48h, and no obvious degradation and precipitation wereobserved. The loss rate is less than 5% within the expiration date underappropriate storage condition. 

[ SEQUENCE ]

[ ACTIVITY ] 

Interleukin 13 (IL13) is cytokine secreted by many cell types, but especially Thelper type 2 (Th2) cells. IL13 has effects on immune cells that are similar to thoseof the closely related cytokine IL4. Although IL13 is associated primarily with theinduction of airway disease, it also has anti-inflammatory properties. IL13 inducesa class of protein-degrading enzymes, known as matrix metalloproteinases(MMPs), in the airways. Furthermore, IL-13 can induce immunoglobulin E (IgE)secretion from activated human B cells. Besides, Interleukin 13 Receptor Alpha 1(IL13Ra1) has been identified as an interactor of IL13, thus a binding ELISA assaywas conducted to detect the interaction of recombinant rat IL13 and recombinantrat IL13Ra1. Briefly, IL13 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to IL13Ra1-coated microtiterwells and incubated for 2h at 37℃. Wells were washed with PBST and incubatedfor 1h with anti-IL13 pAb, then aspirated and washed 3 times. After incubation withHRP labelled secondary antibody, wells were aspirated and washed 3 times. Withthe addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. Thebinding activity of IL13 and IL13Ra1 was shown in Figure 1, and this effect was ina dose dependent manner.

[ IDENTIFICATION ]

[ IMPORTANT NOTE ] 

The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.

特别提示：本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！以实际收货产品说明书为准，网站说明书仅供参考。